Insider Trading & Ownership of ELI LILLY & Co

Location
Indianapolis, IN
Summary
The estimated value of insider holdings of ELI LILLY & Co is at least $135,446,834 dollars as of 15 Jan 2026. ELI LILLY & Co is the 10%+ Owner of Aktis Oncology, Inc. and owns shares of Aktis Oncology, Inc. (AKTS) stock worth about $135.45M.
Signature
/s/ Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Corporate Secretary
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow ELI LILLY & Co and return when a new Insider Trading filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sign up to follow filing activity

Sponsored

Quick Takeaways

  • ELI LILLY & Co has 2 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $135,446,834.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Aktis Oncology, Inc. ($135,446,834).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Official SEC Source

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of ELI LILLY & Co

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
AKTS Aktis Oncology, Inc. 10%+ Owner $135,446,834 12 Jan 2026
SGTX Sigilon Therapeutics, Inc. 10%+ Owner 11 Aug 2023

Insider Transactions Reported by ELI LILLY & Co:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored